topstockalerts
Nov 13, 3:32 AM
Swiss clinical-stage biotech Windward Bio Group priced its IPO at
$17 per share, offering 10.29 million ordinary shares and targeting approximately
$175 million in gross proceeds. Underwriters have a 30-day option to purchase up to an additional 1.54 million shares at the IPO price.
The company also announced a concurrent
$50 million private placement to Sanofi Foreign Participations, comprising 1.53 million ordinary shares and pre-funded warrants for another 1.41 million shares, also priced at
$17.
Shares were expected to begin trading on the Nasdaq Global Select Market on November 13, 2026, with the IPO closing anticipated on November 16, subject to customary conditions. The private placement is contingent on completion of the IPO. Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are serving as joint book-running managers.
$JEF $PIPR $UBS
